JP2025501731A5 - - Google Patents

Info

Publication number
JP2025501731A5
JP2025501731A5 JP2024536420A JP2024536420A JP2025501731A5 JP 2025501731 A5 JP2025501731 A5 JP 2025501731A5 JP 2024536420 A JP2024536420 A JP 2024536420A JP 2024536420 A JP2024536420 A JP 2024536420A JP 2025501731 A5 JP2025501731 A5 JP 2025501731A5
Authority
JP
Japan
Prior art keywords
cells
optionally substituted
therapeutic
lnp
lnp preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024536420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501731A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/053209 external-priority patent/WO2023121975A1/en
Publication of JP2025501731A publication Critical patent/JP2025501731A/ja
Publication of JP2025501731A5 publication Critical patent/JP2025501731A5/ja
Pending legal-status Critical Current

Links

JP2024536420A 2021-12-20 2022-12-16 イオン化可能なアミン脂質及び脂質ナノ粒子 Pending JP2025501731A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163291639P 2021-12-20 2021-12-20
US63/291,639 2021-12-20
US202263354627P 2022-06-22 2022-06-22
US63/354,627 2022-06-22
PCT/US2022/053209 WO2023121975A1 (en) 2021-12-20 2022-12-16 Ionizable amine lipids and lipid nanoparticles

Publications (2)

Publication Number Publication Date
JP2025501731A JP2025501731A (ja) 2025-01-23
JP2025501731A5 true JP2025501731A5 (cg-RX-API-DMAC10.html) 2025-12-23

Family

ID=85157159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024536420A Pending JP2025501731A (ja) 2021-12-20 2022-12-16 イオン化可能なアミン脂質及び脂質ナノ粒子

Country Status (6)

Country Link
US (1) US20240335385A1 (cg-RX-API-DMAC10.html)
EP (1) EP4452935A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025501731A (cg-RX-API-DMAC10.html)
AU (1) AU2022418511A1 (cg-RX-API-DMAC10.html)
CA (1) CA3241488A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023121975A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7600208B2 (ja) 2019-07-29 2024-12-16 ジョージア テック リサーチ コーポレイション 拘束された脂質を含むナノ材料およびその使用
CN115175894B (zh) 2020-01-09 2024-09-06 盖德治疗有限责任公司 纳米材料
CN116761888A (zh) 2021-01-20 2023-09-15 比姆医疗股份有限公司 纳米材料
EP4281080A4 (en) 2021-01-20 2025-09-24 Beam Therapeutics Inc NANOMATERIALS COMPRISING A BIODEGRADABLE ELEMENT
WO2024078614A1 (zh) * 2022-10-13 2024-04-18 深圳深信生物科技有限公司 用于递送生物活性成分的氨基脂质化合物和脂质纳米颗粒
US20250381150A1 (en) 2024-03-08 2025-12-18 Genzyme Corporation Lipid nanoparticles
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof
WO2026142951A1 (en) 2024-12-23 2026-07-02 Genzyme Corporation Pharmaceutical system
US20260183424A1 (en) * 2024-12-26 2026-07-02 Eisai R&D Management Co., Ltd. Ionizable lipids for nucleic acid delivery

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1021549A2 (en) 1997-09-19 2000-07-26 Sequitur, Inc. SENSE mRNA THERAPY
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
EP4481047A3 (en) * 2010-06-03 2025-04-16 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
DE21212055T1 (de) * 2011-12-07 2022-08-04 Alnylam Pharmaceuticals, Inc. Biologisch abbaubare lipide zur freisetzung von wirkstoffen
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
US10426737B2 (en) * 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
CN111542338B (zh) * 2017-12-27 2024-06-18 武田药品工业株式会社 含核酸脂质纳米粒子及其用途
EP3924479A4 (en) 2019-02-13 2023-01-25 Beam Therapeutics, Inc. ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING THEM TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE
WO2020219876A1 (en) * 2019-04-25 2020-10-29 Intellia Therapeutics, Inc. Ionizable amine lipids and lipid nanoparticles
CA3143865A1 (en) * 2019-06-07 2020-12-10 Fujifilm Corporation Lipid composition

Similar Documents

Publication Publication Date Title
JP2025500824A5 (cg-RX-API-DMAC10.html)
JP7654724B2 (ja) 治療剤の細胞内送達のための化合物および組成物
JP2024505449A5 (cg-RX-API-DMAC10.html)
JP2024508347A5 (cg-RX-API-DMAC10.html)
JP2024503441A5 (cg-RX-API-DMAC10.html)
AU2019277361B2 (en) Messenger RNA vaccines and uses thereof
JP4491136B2 (ja) 関節症を治療するためのファルネシルタンパク質トランスフェラーゼ阻害剤
TWI269652B (en) Transnasal anticonvulsive compositions and modulated process
JP2024502954A5 (cg-RX-API-DMAC10.html)
EA033966B1 (ru) Стереохимически обогащенные композиции для доставки нуклеиновых кислот
RU2126417C1 (ru) Сложные эфиры нуклеозидов, фармацевтическая композиция
JP2024503976A5 (cg-RX-API-DMAC10.html)
JP2009533457A (ja) C−ニトロソから誘導されるニトロキシル供与体
JP2002538200A (ja) 長鎖炭化水素およびヌクレオシド類似体によるウイルス複製の相乗的阻害
JP2002527522A (ja) 慢性C型肝炎感染を有する患者における検出可能HCV−RNA根絶用リバビリン−インターフェロン−α併用療法
WO2025146125A1 (zh) 用于递送的脂质化合物和脂质纳米颗粒
CN117430541B (zh) 用于向细胞递送的化合物及其组合物
JP2025533111A (ja) Rnaコンストラクト及びその使用
CN117899048A (zh) 一种靶向脂质纳米粒及其制备与应用
WO2024078614A1 (zh) 用于递送生物活性成分的氨基脂质化合物和脂质纳米颗粒
CN120754284B (zh) 一种用于肝脏靶向联合递送CRISPR-Cas9系统和单链DNA修复模板的脂质纳米颗粒
KR20250164231A (ko) 작용제의 전달을 위한 지질 나노입자
JP7842738B2 (ja) バイオインスパイアード脂質誘導体及びその使用
KR20240167649A (ko) 아미노 지질 화합물, 이의 제조 방법, 이의 조성물 및 이의 용도
CN100367948C (zh) 三环-[5.2.1.02.6]-癸-9-基-黄原酸酯的纯立体异构体的制备和由其制成的药物